Should antiplatelet agents (e.g., aspirin, clopidogrel) be discontinued before a tracheostomy?

Antiplatelet Management for Tracheostomy

For patients on aspirin alone undergoing tracheostomy, continue the aspirin without interruption; for patients on clopidogrel or dual antiplatelet therapy, the decision is more nuanced and depends on bleeding risk versus thrombotic risk, but recent evidence supports continuation of low-dose aspirin is safe.

Risk-Benefit Framework

Tracheostomy is not specifically addressed in the 2022 CHEST guidelines 1, which focus on minor dental, dermatologic, and ophthalmologic procedures where antiplatelet continuation is recommended. However, the principles can be extrapolated with important caveats about bleeding risk.

Aspirin Management

• Low-dose aspirin (81 mg) can be safely continued through tracheostomy based on recent evidence showing no increase in major or minor bleeding complications 2
• The 2026 study comparing aspirin continuation versus discontinuation in open tracheostomy found zero bleeding events in the continuation group versus 12.6% combined major/minor bleeding in the discontinuation group (though not statistically significant due to small sample size) 2
• This aligns with the general principle that aspirin increases intraoperative bleeding only moderately without increasing transfusion requirements 3

Clopidogrel (P2Y12 Inhibitor) Management

The decision for clopidogrel is more complex and requires weighing:

If clopidogrel must be interrupted:

• Stop 5 days prior to tracheostomy to allow platelet function recovery 4
• P2Y12 inhibitors affect platelets for their 7-10 day lifespan 4
• Resume clopidogrel as soon as hemostasis is achieved postoperatively 4

Critical exception - DO NOT stop clopidogrel if:

• Within 6 weeks of bare-metal stent placement
• Within 3-6 months of myocardial infarction
• Within 12 months of drug-eluting stent placement 5
• In these scenarios, perform tracheostomy under continued antiplatelet therapy as the thrombotic risk (5-10 fold increase in MI/death) far exceeds bleeding risk 5, 6, 7

Dual Antiplatelet Therapy (DAPT)

For patients on both aspirin and clopidogrel:

• Continue aspirin, consider interrupting clopidogrel only if beyond the critical stent/MI timeframes noted above 1
• If within high-risk thrombotic windows, continue both agents and accept increased bleeding risk (approximately 50% increase) 5

Key Clinical Pitfalls

1. Never abruptly stop antiplatelet therapy in recent stent patients - this creates a 10% risk of major vascular events and potential fatal stent thrombosis 6

2. Tracheostomy is not a closed-space procedure - unlike intracranial or posterior eye chamber surgery where even aspirin should be stopped, tracheostomy allows for direct hemostatic control 5, 7

3. Platelet transfusions have limited utility - they are ineffective within 4 hours of clopidogrel loading dose or 2 hours of maintenance dose 4; only give for active bleeding

4. Do not substitute with heparin/LMWH - this does not protect against coronary or stent thrombosis 7

Practical Algorithm

1. Identify indication for antiplatelet therapy:

   • Primary prevention only → Can stop 5-7 days prior
   • Secondary prevention (prior MI/stroke/PAD) → Continue aspirin
   • Recent stent (<timeframes above) → Continue all agents

2. Assess bleeding risk of tracheostomy:

   • Open surgical tracheostomy with direct visualization → Lower concern
   • Percutaneous tracheostomy → Similar risk profile
   • Coagulopathy or anatomic concerns → May warrant stopping clopidogrel if safe from thrombotic standpoint

3. For urgent/emergent tracheostomy:

   • Proceed regardless of antiplatelet status
   • Have surgical hemostatic measures ready
   • Consider platelet transfusion only if active bleeding occurs

The contemporary evidence strongly favors continuing aspirin through tracheostomy, with selective interruption of clopidogrel only when thrombotic risk permits.